 Atossa Therapeutics Inc NASDAQ: ATOS has announced final data from its Phase 2 study of oral Endoxifen administered between the diagnosis of breast cancer and surgery. The study enrolled seven newly-diagnosed patients with ER and human epidermal growth factor receptor 2 negative HER2- stage 1 or 2 invasive breast cancer, requiring mastectomy or lumpectomy. 